These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8731307)

  • 1. [The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty].
    Pimentel Filho WA
    Arq Bras Cardiol; 1995 Dec; 65(6):517-8. PubMed ID: 8731307
    [No Abstract]   [Full Text] [Related]  

  • 2. [The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty].
    Cláudio Correia LC; Neubauer C; Azevedo A; Ribeiro F; Braga J; Carlos Passos L; Teixeira M; Matos M; Aires V; Souza V
    Arq Bras Cardiol; 1995 Dec; 65(6):475-8. PubMed ID: 8731298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease.
    Krulewitz A
    N Engl J Med; 1998 Jan; 338(2):130; author reply 131. PubMed ID: 9424584
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease.
    Goodall AH; Knight C
    N Engl J Med; 1998 Jan; 338(2):130-1. PubMed ID: 9424585
    [No Abstract]   [Full Text] [Related]  

  • 5. Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on.
    Antman EM
    Am Heart J; 2003 Aug; 146(2):191-3. PubMed ID: 12891179
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
    Wong GC; Giugliano RP
    Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 8. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining treatment strategies in the 21st century: low-molecular-weight heparins in acute coronary syndromes.
    Zidar JP
    J Invasive Cardiol; 2000 Mar; 12 Suppl B():16B-21B. PubMed ID: 10731295
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease.
    Kearon C
    N Engl J Med; 1998 Jan; 338(2):129-30; author reply 131. PubMed ID: 9424582
    [No Abstract]   [Full Text] [Related]  

  • 12. Heparin in coronary artery disease: new uses for an old drug.
    Violaris AG; Angelini GD
    Br J Hosp Med; 1993 Jan 6-19; 49(1):37-9, 42-3. PubMed ID: 8347182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous coronary intervention or thrombolytics in ST-elevation infarction. What is the emperor really wearing?
    Dellborg M
    Scand Cardiovasc J; 2002 Aug; 36(4):197-200. PubMed ID: 12201965
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
    Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
    J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reliable anticoagulation in acute myocardial infarction. Acute coronary syndromes: advances with low-molecular heparin therapy].
    Z Kardiol; 1998 Dec; 87(12 Suppl Akute Koro):1-4. PubMed ID: 9884738
    [No Abstract]   [Full Text] [Related]  

  • 17. Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.
    Bassand JP; Berthe C; Bethencourt A; Bolognese L; Wójcik J;
    Curr Med Res Opin; 2003; 19(2):107-13. PubMed ID: 12740154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of low-molecular-weight heparin in acute coronary syndromes].
    Gharbi M; Barakett N; Lahidheb DH; Smiri Z; Fehri W; Azzouzi F; Rahal N; Mhenni H; Haouala H; Guediche M
    Tunis Med; 2002 Dec; 80(12):725-32. PubMed ID: 12664498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins].
    López-Sendón J; López de Sá E; Rubio Sanz R; Delcán Domínguez JL
    Rev Esp Cardiol; 1999; 52 Suppl 1():76-89. PubMed ID: 10364817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation committees' methods for appraising new drugs. Committee failed to meet aims in producing report on low molecular weight heparins.
    Bosanquet N; Fox K
    BMJ; 2000 Mar; 320(7236):714-5. PubMed ID: 10710594
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.